184 related articles for article (PubMed ID: 24965535)
21. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
Czyz A; Lewandowski K; Kroll R; Komarnicki M
Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
[TBL] [Abstract][Full Text] [Related]
22. Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions.
Yoshimitsu M; Fujiwara H; Ozaki A; Hamada H; Matsushita K; Arima N; Tei C
Int J Hematol; 2008 Oct; 88(3):331-335. PubMed ID: 18696183
[TBL] [Abstract][Full Text] [Related]
23. Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study.
Guan F; Yang L; Chen Y; Shi J; Song X; Lai X; Lu Y; Liu L; Ouyang G; Zhao Y; Yu J; Xu Y; Lan J; Fu H; Zhao Y; Qiu X; Zhu P; Cai Z; Huang H; Luo Y
Cancer; 2024 Jun; 130(12):2139-2149. PubMed ID: 38315517
[TBL] [Abstract][Full Text] [Related]
24. Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia.
Chang J; Douer D; Aldoss I; Vahdani G; Jeong AR; Ghaznavi Z; Zhang S; Yaghmour G; Lee KJ; Weissman A; Akhtari M
Cancer Med; 2019 Jun; 8(6):2832-2839. PubMed ID: 31016870
[TBL] [Abstract][Full Text] [Related]
25. The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Zhang FH; Ling YW; Zhai X; Zhang Y; Huang F; Fan ZP; Zhou HS; Jiang QL; Sun J; Liu QF
Hematology; 2013 May; 18(3):151-7. PubMed ID: 23394269
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic analysis of allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in complete remission in the era of tyrosine kinase inhibitors].
Cao XY; Ma W; Zhang W; Liu DY; Zhao YL; Lu Y; Zhang JP; Zhou JR; Xiong M; Wei ZJ; Sun RJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):564-569. PubMed ID: 32810963
[No Abstract] [Full Text] [Related]
27. Twenty years' experience in allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in the Nagoya Blood and Marrow Transplantation Group.
Iida H; Sao H; Kitaori K; Gotoh S; Yazaki M; Kojima S; Wakita A; Morishima Y; Kodera Y; Morishita Y
Int J Hematol; 2004 Jan; 79(1):79-84. PubMed ID: 14979483
[TBL] [Abstract][Full Text] [Related]
28. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.
Chalandon Y; Thomas X; Hayette S; Cayuela JM; Abbal C; Huguet F; Raffoux E; Leguay T; Rousselot P; Lepretre S; Escoffre-Barbe M; Maury S; Berthon C; Tavernier E; Lambert JF; Lafage-Pochitaloff M; Lhéritier V; Chevret S; Ifrah N; Dombret H;
Blood; 2015 Jun; 125(24):3711-9. PubMed ID: 25878120
[TBL] [Abstract][Full Text] [Related]
29. [Risk Factors of Leukemia-free Survival in Ph
Bao XB; Cai WZ; He XF; Chen SN; Qiu HY; Sun AN; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1787-1792. PubMed ID: 29262917
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Wang J; Jiang Q; Xu LP; Zhang XH; Chen H; Qin YZ; Ruan GR; Jiang H; Jia JS; Zhao T; Liu KY; Jiang B; Huang XJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):741-750. PubMed ID: 29247779
[TBL] [Abstract][Full Text] [Related]
31. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Min CK; Kim HJ; Eom KS; Kim DW; Lee JW; Min WS; Kim CC
Blood; 2005 May; 105(9):3449-57. PubMed ID: 15657178
[TBL] [Abstract][Full Text] [Related]
32. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Gruber F; Mustjoki S; Porkka K
Br J Haematol; 2009 Jun; 145(5):581-97. PubMed ID: 19388927
[TBL] [Abstract][Full Text] [Related]
33. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
34. Comparative study on allogeneic with autologous hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of TKIs: a systematic review and meta-analysis.
Wei H; Kuang P; Liu T
Ann Hematol; 2020 Nov; 99(11):2619-2628. PubMed ID: 32960314
[TBL] [Abstract][Full Text] [Related]
35. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.
Kebriaei P; Saliba R; Rondon G; Chiattone A; Luthra R; Anderlini P; Andersson B; Shpall E; Popat U; Jones R; Worth L; Ravandi F; Thomas D; O'Brien S; Kantarjian H; de Lima M; Giralt S; Champlin R
Biol Blood Marrow Transplant; 2012 Apr; 18(4):584-92. PubMed ID: 21867666
[TBL] [Abstract][Full Text] [Related]
37. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
Fielding AK; Rowe JM; Buck G; Foroni L; Gerrard G; Litzow MR; Lazarus H; Luger SM; Marks DI; McMillan AK; Moorman AV; Patel B; Paietta E; Tallman MS; Goldstone AH
Blood; 2014 Feb; 123(6):843-50. PubMed ID: 24277073
[TBL] [Abstract][Full Text] [Related]
38. Haploidentical allogeneic hematopoietic stem cell transplantation compared to matched unrelated transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Gu B; Wu X; Chen G; Ma X; Jin Z; Tang X; Han Y; Fu C; Qiu H; Sun A; Wu D
Leuk Res; 2017 Aug; 59():41-46. PubMed ID: 28549237
[TBL] [Abstract][Full Text] [Related]
39. Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ohno R
Curr Oncol Rep; 2008 Sep; 10(5):379-87. PubMed ID: 18706265
[TBL] [Abstract][Full Text] [Related]
40. [Allogeneic hematopoietic stem cell transplantation combined with imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia].
Cai B; Gao CJ; Li HH; Bo J; Huang WR; Gao L; Sun JF; Ding Y; Wang LL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):173-6. PubMed ID: 20137141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
